HIV-1-infection

Showing NaN - NaN of 8

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

HIV-1-infection Trial in Brazil, United States (ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3)

Not yet recruiting
  • HIV-1-infection
  • ChAdOx1.tHIVconsv1
  • +7 more
  • San Diego, California
  • +11 more
Oct 4, 2023

HIV-1-infection Trial in Worldwide (Once daily CAB tablet + RPV tablet, Long acting CAB injectable + long acting RPV injectable)

Not yet recruiting
  • HIV-1-infection
  • Once daily CAB tablet + RPV tablet
  • Long acting CAB injectable + long acting RPV injectable
  • Atlanta, Georgia
  • +11 more
Dec 13, 2022

HIV-1-infection Trial in Worldwide (Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir)

Active, not recruiting
  • HIV-1-infection
  • Oral Lenacapavir
  • +4 more
  • Los Angeles, California
  • +74 more
Oct 17, 2022

HIV-1-infection Trial in United States (426c.Mod.Core-C4b 30 mcg, 426c.Mod.Core-C4b 100 mcg, 426c.Mod.Core-C4b 300 mcg)

Recruiting
  • HIV-1-infection
  • 426c.Mod.Core-C4b 30 mcg
  • +3 more
  • Birmingham, Alabama
  • +5 more
Jul 25, 2022

HIV-1-infection Trial in Worldwide (B/F/TAF, F/TAF, DTG)

Completed
  • HIV-1-infection
  • Phoenix, Arizona
  • +93 more
Dec 14, 2021

HIV-1-infection Trial in United States (Albuvirtide, 3BNC117, Baseline ART)

Recruiting
  • HIV-1-infection
  • Palm Springs, California
  • +6 more
Sep 28, 2021

HIV/AIDS, HIV-1-infection, Osteopenia Trial in United States (Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE

Withdrawn
  • HIV/AIDS
  • +2 more
  • Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)
  • Current tenofovir alafenamide (TAF)-containing ART regimen
  • Birmingham, Alabama
  • +9 more
Mar 10, 2021

HIV-1 Reservoir in Central Nervous System of

Completed
  • HIV-1-infection
    • Los Angeles, California
    • +11 more
    Jul 7, 2020